Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)

Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020–2022. The IgG batches (from US plasma) showed potent activity. Intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Díez, José María, Casals, Daniel, Romero, Carolina, Gajardo, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253882/
https://www.ncbi.nlm.nih.gov/pubmed/35794931
http://dx.doi.org/10.1093/ofid/ofac216
_version_ 1784740587851743232
author Díez, José María
Casals, Daniel
Romero, Carolina
Gajardo, Rodrigo
author_facet Díez, José María
Casals, Daniel
Romero, Carolina
Gajardo, Rodrigo
author_sort Díez, José María
collection PubMed
description Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020–2022. The IgG batches (from US plasma) showed potent activity. Intravenous immunoglobulin could potentially add to therapies for serious influenza cases in immunocompromised patients. Further study is warranted.
format Online
Article
Text
id pubmed-9253882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92538822022-07-05 Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022) Díez, José María Casals, Daniel Romero, Carolina Gajardo, Rodrigo Open Forum Infect Dis Brief Report Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020–2022. The IgG batches (from US plasma) showed potent activity. Intravenous immunoglobulin could potentially add to therapies for serious influenza cases in immunocompromised patients. Further study is warranted. Oxford University Press 2022-04-28 /pmc/articles/PMC9253882/ /pubmed/35794931 http://dx.doi.org/10.1093/ofid/ofac216 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Díez, José María
Casals, Daniel
Romero, Carolina
Gajardo, Rodrigo
Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title_full Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title_fullStr Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title_full_unstemmed Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title_short Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
title_sort medicinal immunoglobulin g products (2020) show high infectivity neutralizing activity against seasonal influenza virus strains selected for future vaccines (2020–2022)
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253882/
https://www.ncbi.nlm.nih.gov/pubmed/35794931
http://dx.doi.org/10.1093/ofid/ofac216
work_keys_str_mv AT diezjosemaria medicinalimmunoglobulingproducts2020showhighinfectivityneutralizingactivityagainstseasonalinfluenzavirusstrainsselectedforfuturevaccines20202022
AT casalsdaniel medicinalimmunoglobulingproducts2020showhighinfectivityneutralizingactivityagainstseasonalinfluenzavirusstrainsselectedforfuturevaccines20202022
AT romerocarolina medicinalimmunoglobulingproducts2020showhighinfectivityneutralizingactivityagainstseasonalinfluenzavirusstrainsselectedforfuturevaccines20202022
AT gajardorodrigo medicinalimmunoglobulingproducts2020showhighinfectivityneutralizingactivityagainstseasonalinfluenzavirusstrainsselectedforfuturevaccines20202022

Ejemplares similares